CBL-514 is under clinical development by Caliway Biopharmaceutics and currently in Phase II for Adiposis Dolorosa (Dercum’s Disease or Anders Disease). According to GlobalData, Phase II drugs for Adiposis Dolorosa (Dercum’s Disease or Anders Disease) does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the CBL-514 LoA Report. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

CBL-514 overview

CBL-514 is under development for the treatment to reduce abdominal subcutaneous fat (obesity), edematous fibrosclerotic panniculopathy (EFP) cellulite, Dercum's disease and benign tumors such as lipoma. The drug candidate is administered through subcutaneous or parenteral route. The drug candidate consists of plurality of drug-containing micelles formed of a polyoxyethylene castor oil derivative and curcumin substances encapsulated in drug-containing micelles. It acts by targeting DYRK1b.

For a complete picture of CBL-514’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.